PharmAust Reports ongoing positive outcomes for canine cancer treatment
- PharmAust (PAA) claims a 12-year-old beagle in its clinical trial for the treatment of canine cancer has so far lived for over 240 days with a high quality of life
- The beagle, Louie, has B-cell lymphoma, which is often fatal within a few weeks, and is being treated solely with the company’s monepantel (MPL) drug
- The company says its drug so far appears to extend survival in dogs three-fold while allowing them to maintain a good quality of life
- So far, PAA has treated 36 dogs using MPL, with 11 having shown a decrease in tumour size
- Shares in The company are trading at 8.6 cents at 2:39 pm AEDT
